Expanded Access Protocol (EAP) For Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release

Grants and Contracts Details

StatusActive
Effective start/end date1/29/219/18/25

Funding

  • Celgene: $42,215.00